Wall Street’s Bullish New Menu: Insider Conviction, OLED Speed, Virtual Care and a Parkinson’s Catalyst -( $AMWL $GME $LPL $PFE $SER $XBI )

The market’s most compelling bullish narratives rarely arrive wearing the same uniform. This week, they span a CEO buying millions of dollars of his own stock, an OLED display running at a downright impolite 720Hz, a telehealth company pursuing large institutional accounts, and a clinical-stage biotech moving its Parkinson’s program forward with its CEO set to discuss the opportunity live this Thursday. At the center of the healthcare story is Serina Therapeutics, Inc. (NYSE American: SER), which will host a Tribe Public CEO Presentation and live Q&A webinar with CEO Steven Ledger on Thursday, September 24, 2026, at 11:30 a.m. ET / 8:30 a.m. PT. Investors can register at AdvancedParkinsonsDisease.TribePublic.com.

GameStop: Ryan Cohen Puts $26.4 Million Behind the Thesis

GameStop Corp. (NYSE: GME) received a fresh dose of a signal Wall Street has always understood: the CEO is buying. Ryan Cohen, GameStop’s chairman and chief executive, purchased 1,150,680 shares of GME on September 21 for approximately $26.4 million. His purchases were made at prices ranging from $22.76 to $23.02 per share, producing a weighted average price of about $22.94. Following the transaction, Cohen directly owned 40,498,522 GameStop shares. The purchase was not disclosed as part of a Rule 10b5-1 prearranged trading plan. In plain English, that matters because it suggests a direct, discretionary decision to increase his ownership—not merely an administrative calendar appointment dressed in securities-law paperwork. GME shares gained following the filing, while Cohen’s latest purchase extended a recent streak of insider accumulation. He reportedly bought another 1 million shares earlier in September at an average price near $20.38.

Why GME has attention

The bullish argument is not that GameStop’s transformation is complete; it plainly is not. The more relevant point is that Cohen continues to build a larger personal stake while the company has worked to strengthen its financial position and preserve strategic flexibility. Many will watch whether management converts that flexibility into durable earnings power, disciplined capital allocation and a clearer commercial identity. For now, the CEO has made one element of the story unusually clear: he would rather own more GME than less.

LG Display: Gaming OLED Hits 720Hz

LG Display Co., Ltd. (NYSE: LPL; KRX: 034220) has launched a 24.5-inch gaming OLED panel with a 720Hz refresh rate, putting it squarely in the fast-growing intersection of premium displays, competitive gaming and esports. The company says the OLED panel delivers a 0.02-millisecond response time and reaches 720Hz at full-HD resolution through a proprietary driving algorithm. It is slated for ASUS’s ROG Swift OLED PG259QWS Ace, which LG Display says has been selected as an official monitor for the PGL CS2 Major Singapore 2026 tournament. ASUSTeK Computer Inc. trades on the Taiwan Stock Exchange under ticker 2357.

Why LPL can matter

At 720Hz, the phrase “blink and you’ll miss it” begins to sound less like a cliché and more like a product feature. For elite esports players, display performance is not a luxury category, it is competitive equipment. For LG Display, the launch supports the larger investment thesis that OLED technology can continue expanding beyond televisions and mobile devices into specialized, higher-value display segments. Premium gaming monitors may not be the largest display market, but they can be an influential one: enthusiasts and professional gamers are unusually willing to pay for responsiveness, contrast, motion clarity and bragging rights measured in refresh rates.

Amwell: The Enterprise Telehealth Reset

American Well Corp. (NYSE: AMWL), operating as Amwell, is advancing a more focused virtual-care strategy geared toward institutional clients that can support longer-duration revenue relationships. At the Morgan Stanley Global Healthcare Conference, Amwell discussed its Defense Health Agency platform launch and a letter of intent from the U.S. Department of Veterans Affairs. The company also highlighted potential demand from health plans seeking changes to their virtual-care arrangements. That shift could prove meaningful. The telehealth market’s earlier era was marked by exceptionally rapid adoption and equally rapid expectations. The current phase is less theatrical and arguably more investable: virtual-care vendors must demonstrate that their technology can handle complex enterprise needs, integrate into health systems and support favorable unit economics.

AMWL’s opportunity

Amwell’s path does not require it to become the loudest name in telehealth. It needs to become a trusted platform partner for payers, provider systems and government organizations. Management said it has met financial commitments for eight consecutive quarters and approached breakeven, while identifying a potential opportunity worth hundreds of millions of dollars over the coming years. The critical test will be whether contract activity becomes sustainable revenue growth and meaningful improvement in profitability. AMWL shares are trading currently at $13.50 and up 174.85% YTD.

Serina: Clinical Momentum Meets an Investor Event

Serina Therapeutics is developing SER-252, a long-acting apomorphine-based therapy candidate designed for people with advanced Parkinson’s disease. The program is being evaluated in a Phase 1b registrational study, and Serina recently reported that an independent Safety Monitoring Committee recommended advancing the study from Cohort 1 to Cohort 2 after a blinded review. The company said Cohort 1 generated observations consistent with sustained apomorphine exposure, with individual patients showing periods of motor-function improvement on exploratory measures. Serina expects topline data from the single-ascending-dose portion of the study during the first half of 2027. Early clinical data are inherently preliminary and should not be treated as proof of efficacy, but advancement through the next cohort is a tangible execution milestone for a development-stage biotechnology company.

Tribe Public webinar details

Serina CEO Steven Ledger will present the company’s advanced Parkinson’s disease strategy and discuss the clinical progress of SER-252 during a Tribe Public CEO Presentation & Q&A Webinar Event.

The webinar gives investors an opportunity to hear directly from Serina’s leadership on the rationale for SER-252, the clinical-development plan, the advanced Parkinson’s market and the milestones that could shape the company’s next phase. For a clinical-stage story, direct discussion of timeline, data interpretation, manufacturing, financing and regulatory strategy can be more useful than trying to read the tea leaves from a single press release.

What makes SER notable

SER-252 is designed to address motor fluctuations in advanced Parkinson’s disease, a population in which patients may remain inadequately controlled on oral therapies. Serina’s development plan uses its proprietary POZ technology platform to pursue sustained drug exposure, while the company has described a 505(b)(2) regulatory strategy for the program. The clinical opportunity remains high risk, as it does for virtually every development-stage biotechnology company. Serina still must generate persuasive safety, pharmacokinetic and clinical data, secure adequate funding, execute its trial and navigate regulatory review. Yet the advance to Cohort 2 gives investors a clear near-term marker of forward progress rather than a science project parked indefinitely in the laboratory. Pfizer Inc. (NYSE: PFE) remains a major large-cap biopharma reference point for investors tracking neurology and Parkinson’s-related innovation, while the SPDR S&P Biotech ETF (NYSE Arca: XBI) remains a useful sentiment indicator for emerging biotechnology. Neither PFE nor XBI should be viewed as a direct proxy for SER’s clinical or financial outcome.

The Bullish Throughline

The common thread across GameStop, LG Display, Amwell and Serina is evidence of execution—not guarantees, and certainly not a request to suspend skepticism at the door.

For GME, the signal is insider conviction. For LPL, it is product innovation moving at a speed that would make a hummingbird ask for a software update. For AMWL, it is disciplined focus on customers capable of supporting durable platform economics. And for SER, it is the prospect of advancing an important clinical program while giving investors a direct forum with company leadership.

The Sources

1. Yahoo Finance “GameStop stock jumps as CEO Ryan Cohen buys $26 million in shares”
2. Investing.com “GameStop president Ryan Cohen buys $26.4m in GME stock”
3. Stock Titan GameStop Form 4: Ryan Cohen insider purchase
4. Yahoo Finance “LG Display launches 24.5-inch 720Hz Gaming OLED Panel”
5. Investing.com Amwell at Morgan Stanley conference: pivot toward government and payers
6. Serina Therapeutics / SEC Form 8-K SER-252 study update and Cohort 2 advancement
7. BioSpace “Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2”
8. Parkinson’s News Today Wearable-delivered Parkinson’s therapy shows promise in early trial
9. Vista Partners “Serina Therapeutics Brings a Fresh Dose of Momentum to Advanced Parkinson’s Care”
10. Tribe Public Serina Therapeutics CEO Presentation & Q&A Webinar Registration